JPWO2020036997A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020036997A5
JPWO2020036997A5 JP2021506718A JP2021506718A JPWO2020036997A5 JP WO2020036997 A5 JPWO2020036997 A5 JP WO2020036997A5 JP 2021506718 A JP2021506718 A JP 2021506718A JP 2021506718 A JP2021506718 A JP 2021506718A JP WO2020036997 A5 JPWO2020036997 A5 JP WO2020036997A5
Authority
JP
Japan
Prior art keywords
alkyl
use according
aryl
heteroaryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534116A (ja
JP2021534116A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046408 external-priority patent/WO2020036997A1/en
Publication of JP2021534116A publication Critical patent/JP2021534116A/ja
Publication of JP2021534116A5 publication Critical patent/JP2021534116A5/ja
Publication of JPWO2020036997A5 publication Critical patent/JPWO2020036997A5/ja
Pending legal-status Critical Current

Links

JP2021506718A 2018-08-14 2019-08-13 再発性の濾胞性リンパ腫の処置 Pending JP2021534116A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US62/718,926 2018-08-14
US201962836507P 2019-04-19 2019-04-19
US62/836,507 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (3)

Publication Number Publication Date
JP2021534116A JP2021534116A (ja) 2021-12-09
JP2021534116A5 JP2021534116A5 (https=) 2022-08-19
JPWO2020036997A5 true JPWO2020036997A5 (https=) 2022-08-19

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506718A Pending JP2021534116A (ja) 2018-08-14 2019-08-13 再発性の濾胞性リンパ腫の処置

Country Status (14)

Country Link
US (1) US20210196725A1 (https=)
EP (1) EP3836936A4 (https=)
JP (1) JP2021534116A (https=)
KR (1) KR20210043637A (https=)
CN (1) CN112839659A (https=)
AU (1) AU2019321526A1 (https=)
BR (1) BR112021002734A2 (https=)
CA (1) CA3109377A1 (https=)
IL (1) IL280721A (https=)
MA (1) MA53237A (https=)
MX (1) MX2021001765A (https=)
SG (1) SG11202101417XA (https=)
TW (1) TW202021593A (https=)
WO (1) WO2020036997A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
BR112015002285B1 (pt) * 2012-08-09 2022-05-10 Celgene Corporation Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Similar Documents

Publication Publication Date Title
JP2024050527A5 (https=)
JP2020023528A5 (https=)
JP2019524883A5 (https=)
RU2005128190A (ru) Ингибиторы фактора подавления миграции макрофагов (фпм) и способы их идентификации
JP2014509647A5 (https=)
JP2014500870A5 (https=)
JP2021517116A5 (https=)
JP2015536986A5 (https=)
JP2017508816A5 (https=)
KR20150140419A (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
JP2021535112A5 (https=)
JP2021525278A5 (https=)
JP2020503341A5 (https=)
JP2020531414A5 (https=)
JP2021534116A5 (https=)
JP2019529460A5 (https=)
JP2020111571A5 (https=)
JP2021534115A5 (https=)
JPWO2019183226A5 (https=)
JPWO2020036997A5 (https=)
JPWO2020033520A5 (https=)
JPH02193980A (ja) 増感剤として有用なニトロイミダゾール類の新規合成法
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины
JP2022502378A5 (https=)
JP2021510168A5 (https=)